{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:35:38Z","timestamp":1785173738715,"version":"3.55.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T00:00:00Z","timestamp":1689033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-02107-5","type":"journal-article","created":{"date-parts":[[2023,7,11]],"date-time":"2023-07-11T07:02:06Z","timestamp":1689058926000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The effects of STA-9090 (Ganetespib) and venetoclax (ABT-199) combination on apoptotic pathways in human cervical cancer cells"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9813-4255","authenticated-orcid":false,"given":"Dilay","family":"Karademir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aykut","family":"\u00d6zg\u00fcr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,11]]},"reference":[{"key":"2107_CR1","doi-asserted-by":"publisher","first-page":"720","DOI":"10.21147\/j.issn.1000-9604.2020.06.05","volume":"32","author":"S Zhang","year":"2020","unstructured":"Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. Chin J Cancer Res. 2020;32:720\u20138.","journal-title":"Chin J Cancer Res"},{"key":"2107_CR2","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72:7\u201333.","journal-title":"CA Cancer J Clin"},{"key":"2107_CR3","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"2107_CR4","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.soncn.2019.02.003","volume":"35","author":"CA Johnson","year":"2019","unstructured":"Johnson CA, James D, Marzan A, Armaos M. Cervical Cancer: an overview of pathophysiology and management. Semin Oncol Nurs. 2019;35:166\u201374.","journal-title":"Semin Oncol Nurs"},{"key":"2107_CR5","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.sxmr.2019.09.005","volume":"8","author":"SL Bedell","year":"2020","unstructured":"Bedell SL, Goldstein LS, Goldstein AR, Goldstein AT. Cervical Cancer screening: past, Present, and Future. Sex Med Rev. 2020;8:28\u201337.","journal-title":"Sex Med Rev"},{"key":"2107_CR6","first-page":"449","volume":"97","author":"J Wipperman","year":"2018","unstructured":"Wipperman J, Neil T, Williams T. Cervical Cancer: evaluation and management. Am Fam Physician. 2018;97:449\u201354.","journal-title":"Am Fam Physician"},{"key":"2107_CR7","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ctrv.2008.05.006","volume":"4","author":"D Pectasides","year":"2008","unstructured":"Pectasides D, Kamposioras K, Papaxoinis G, Pectasides E. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev. 2008;4:603\u201313.","journal-title":"Cancer Treat Rev"},{"key":"2107_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/ncponc0486","volume":"3","author":"PJ Eifel","year":"2006","unstructured":"Eifel PJ. Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. Nat Clin Pract Oncol. 2006;3:248\u201355.","journal-title":"Nat Clin Pract Oncol"},{"key":"2107_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ctrv.2006.09.007","volume":"33","author":"S Tzioras","year":"2007","unstructured":"Tzioras S, Pavlidis N, Paraskevaidis E, Ioannidis JP. Effects of different chemotherapy regimens on survival for advanced cervical cancer: systematic review and meta-analysis. Cancer Treat Rev. 2007;33:24\u201338.","journal-title":"Cancer Treat Rev"},{"key":"2107_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/nrm.2017.20","volume":"18","author":"FH Schopf","year":"2017","unstructured":"Schopf FH, Biebl MM, Buchner J. The HSP90 chaperone machinery. Nat Rev Mol Cell Biol. 2017;18:345\u201360.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2107_CR11","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.2174\/1389201017666161031105815","volume":"17","author":"M G\u00fcmus","year":"2016","unstructured":"G\u00fcmus M, Ozgur A, Tutar L, Disli A, Koca I, Tutar Y, Design. Synthesis, and evaluation of heat shock protein 90 inhibitors in human breast Cancer and its metastasis. Curr Pharm Biotechnol. 2016;17:1231\u201345.","journal-title":"Curr Pharm Biotechnol"},{"key":"2107_CR12","doi-asserted-by":"publisher","first-page":"280","DOI":"10.2174\/1871520615666150821093747","volume":"16","author":"A \u00d6zg\u00fcr","year":"2016","unstructured":"\u00d6zg\u00fcr A, Tutar Y. Heat shock protein 90 inhibition in Cancer Drug Discovery: from Chemistry to Futural Clinical Applications. Anticancer Agents Med Chem. 2016;16:280\u201390.","journal-title":"Anticancer Agents Med Chem"},{"key":"2107_CR13","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.3390\/cells11162556","volume":"11","author":"X Ren","year":"2022","unstructured":"Ren X, Li T, Zhang W, Yang X. Targeting heat-shock protein 90 in Cancer: an update on combination therapy. Cells. 2022;11:2556.","journal-title":"Cells"},{"key":"2107_CR14","doi-asserted-by":"publisher","first-page":"112063","DOI":"10.1016\/j.ejmech.2020.112063","volume":"189","author":"TEMM Costa","year":"2020","unstructured":"Costa TEMM, Raghavendra NM, Penido C. Natural heat shock protein 90 inhibitors in cancer and inflammation. Eur J Med Chem. 2020;189:112063.","journal-title":"Eur J Med Chem"},{"issue":"5","key":"2107_CR15","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1021\/acs.jmedchem.9b00940","volume":"63","author":"L Li","year":"2020","unstructured":"Li L, Wang L, You QD, Xu XL. Heat shock protein 90 inhibitors: an Update on Achievements, Challenges, and future directions. J Med Chem. 2020;63(5):1798\u2013822.","journal-title":"J Med Chem"},{"key":"2107_CR16","doi-asserted-by":"publisher","first-page":"916","DOI":"10.2174\/1871520615666150407155623","volume":"15","author":"\u0130 Koca","year":"2015","unstructured":"Koca \u0130, G\u00fcm\u00fc\u015f M, \u00d6zg\u00fcr A, Di\u015fli A, Tutar Y. A Novel Approach to Inhibit Heat Shock Response as Anticancer Strategy by Coumarine Compounds Containing Thiazole Skeleton. Anticancer Agents Med Chem. 2015;15:916\u201330.","journal-title":"Anticancer Agents Med Chem"},{"key":"2107_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.tibs.2014.12.002","volume":"40","author":"GE Karag\u00f6z","year":"2015","unstructured":"Karag\u00f6z GE, R\u00fcdiger SG. Hsp90 interaction with clients. Trends Biochem Sci. 2015;40:117\u201325.","journal-title":"Trends Biochem Sci"},{"key":"2107_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/15748928113089990031","volume":"9","author":"K Sidera","year":"2014","unstructured":"Sidera K, Patsavoudi E. HSP90 inhibitors: current development and potential in cancer therapy. Recent Pat Anticancer Drug Discov. 2014;9:1\u201320.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"1","key":"2107_CR19","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1158\/1078-0432.CCR-11-1000","volume":"18","author":"L Neckers","year":"2012","unstructured":"Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res. 2012;18(1):64\u201376.","journal-title":"Clin Cancer Res"},{"key":"2107_CR20","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1080\/1120009X.2021.1908650","volume":"33","author":"A \u00d6zg\u00fcr","year":"2021","unstructured":"\u00d6zg\u00fcr A. Investigation of anticancer activities of STA-9090 (ganetespib) as a second generation HSP90 inhibitor in Saos-2 osteosarcoma cells. J Chemother. 2021;33:554\u201363.","journal-title":"J Chemother"},{"key":"2107_CR21","doi-asserted-by":"publisher","first-page":"2997","DOI":"10.2147\/OTT.S245813","volume":"13","author":"L Guan","year":"2020","unstructured":"Guan L, Zou Q, Liu Q, Lin Y, Chen S. HSP90 inhibitor Ganetespib (STA-9090) inhibits Tumor Growth in c-Myc-dependent esophageal squamous cell carcinoma. Onco Targets Ther. 2020;13:2997\u20133011.","journal-title":"Onco Targets Ther"},{"key":"2107_CR22","first-page":"1466","volume":"11","author":"Y Wang","year":"2010","unstructured":"Wang Y, Trepel JB, Neckers LM, Giaccone G. STA-9090, a small-molecule Hsp90 inhibitor for the potential treatment of cancer. Curr Opin Investig Drugs. 2010;11:1466\u201376.","journal-title":"Curr Opin Investig Drugs"},{"key":"2107_CR23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.exphem.2018.02.002","volume":"61","author":"J Mihalyova","year":"2018","unstructured":"Mihalyova J, Jelinek T, Growkova K, Hrdinka M, Simicek M, Hajek R. Venetoclax: a new wave in hematooncology. Exp Hematol. 2018;61:10\u201325.","journal-title":"Exp Hematol"},{"key":"2107_CR24","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s40265-020-01433-6","volume":"80","author":"HA Blair","year":"2020","unstructured":"Blair HA, Venetoclax. A review in previously untreated chronic lymphocytic leukaemia. Drugs. 2020;80:1973\u201380.","journal-title":"Drugs"},{"key":"2107_CR25","doi-asserted-by":"publisher","first-page":"212574","DOI":"10.7573\/dic.212574","volume":"8","author":"LM Ju\u00e1rez-Salcedo","year":"2019","unstructured":"Ju\u00e1rez-Salcedo LM, Desai V, Dalia S. Venetoclax: evidence to date and clinical potential. Drugs Context. 2019;8:212574.","journal-title":"Drugs Context"},{"key":"2107_CR26","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1080\/10428194.2020.1719098","volume":"61","author":"C Lachowiez","year":"2020","unstructured":"Lachowiez C, DiNardo CD, Konopleva M. Venetoclax in acute myeloid leukemia - current and future directions. Leuk Lymphoma. 2020;61:1313\u201322.","journal-title":"Leuk Lymphoma"},{"key":"2107_CR27","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.3389\/fphar.2019.01222","volume":"10","author":"RY Huang","year":"2019","unstructured":"Huang RY, Pei L, Liu Q, Chen S, Dou H, Shu G, Yuan ZX, Lin J, Peng G, Zhang W, Fu H. Isobologram Analysis: a Comprehensive Review of Methodology and Current Research. Front Pharmacol. 2019;10:1222.","journal-title":"Front Pharmacol"},{"key":"2107_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1570164611666140415224635","volume":"11","author":"A \u00d6zg\u00fcr","year":"2014","unstructured":"\u00d6zg\u00fcr A, Tutar Y. Heat shock protein 90 inhibitors in oncology. Curr Proteom. 2014;11:2\u201316.","journal-title":"Curr Proteom"},{"key":"2107_CR29","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.bbamcr.2011.10.008","volume":"1823","author":"K Jhaveri","year":"2012","unstructured":"Jhaveri K, Taldone T, Modi S, Chiosis G. Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers. Biochim Biophys Acta. 2012;1823:742\u201355.","journal-title":"Biochim Biophys Acta"},{"key":"2107_CR30","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2174\/138955706778560166","volume":"6","author":"L Xiao","year":"2006","unstructured":"Xiao L, Lu X, Ruden DM. Effectiveness of hsp90 inhibitors as anti-cancer drugs. Mini Rev Med Chem. 2006;6:1137\u201343.","journal-title":"Mini Rev Med Chem"},{"key":"2107_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.3390\/ph16020230","volume":"16","author":"G Subaiea","year":"2023","unstructured":"Subaiea G, Rizvi SMD, Yadav HKS, Al Hagbani T, Abdallah MH, Khafagy ES, Gangadharappa HV, Hussain T, Abu Lila AS. Ganetespib with Methotrexate Acts synergistically to impede NF-\u03baB\/p65 signaling in Human Lung Cancer A549 cells. Pharmaceuticals (Basel). 2023;16:230.","journal-title":"Pharmaceuticals (Basel)"},{"key":"2107_CR32","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1038\/onc.2013.439","volume":"33","author":"CH Lai","year":"2014","unstructured":"Lai CH, Park KS, Lee DH, Alberobello AT, Raffeld M, Pierobon M, Pin E, Petricoin Iii EF, Wang Y, Giaccone G. HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer. Oncogene. 2014;33:4867\u201376.","journal-title":"Oncogene"},{"key":"2107_CR33","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1007\/s10637-011-9790-6","volume":"30","author":"DA Proia","year":"2012","unstructured":"Proia DA, Sang J, He S, Smith DL, Sequeira M, Zhang C, Liu Y, Ye S, Zhou D, Blackman RK, Foley KP, Koya K, Wada Y. Synergistic activity of the Hsp90 inhibitor ganetespib with taxanes in non-small cell lung cancer models. Invest New Drugs. 2012;30:2201\u20139.","journal-title":"Invest New Drugs"},{"key":"2107_CR34","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.2174\/156802606777812068","volume":"6","author":"DB Solit","year":"2006","unstructured":"Solit DB, Rosen N. Hsp90: a novel target for cancer therapy. Curr Top Med Chem. 2006;6:1205\u201314.","journal-title":"Curr Top Med Chem"},{"key":"2107_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.canlet.2010.10.014","volume":"332","author":"G Jego","year":"2013","unstructured":"Jego G, Hazoum\u00e9 A, Seigneuric R, Garrido C. Targeting heat shock proteins in cancer. Cancer Lett. 2013;332:275\u201385.","journal-title":"Cancer Lett"},{"key":"2107_CR36","doi-asserted-by":"publisher","first-page":"4973","DOI":"10.1158\/1078-0432.CCR-11-2967","volume":"18","author":"T Shimamura","year":"2012","unstructured":"Shimamura T, Perera SA, Foley KP, Sang J, Rodig SJ, Inoue T, Chen L, Li D, Carretero J, Li YC, Sinha P, Carey CD, Borgman CL, Jimenez JP, Meyerson M, Ying W, Barsoum J, Wong KK, Shapiro GI. Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. Clin Cancer Res. 2012;18:4973\u201385.","journal-title":"Clin Cancer Res"},{"key":"2107_CR37","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1007\/s11033-023-08286-8","volume":"50","author":"HE K\u0131z\u0131l","year":"2023","unstructured":"K\u0131z\u0131l HE, Caglayan C, Darendelio\u011flu E, Ayna A, G\u00fcr C, Kandemir FM, K\u00fc\u00e7\u00fckler S. Morin ameliorates methotrexate-induced hepatotoxicity via targeting Nrf2\/HO-1 and Bax\/Bcl2\/Caspase-3 signaling pathways. Mol Biol Rep. 2023;50:3479\u201388.","journal-title":"Mol Biol Rep"},{"key":"2107_CR38","doi-asserted-by":"publisher","first-page":"e202200982","DOI":"10.1002\/cbdv.202200982","volume":"20","author":"H Emre K\u0131z\u0131l","year":"2023","unstructured":"Emre K\u0131z\u0131l H, G\u00fcr C, Ayna A, Darendelio\u011flu E, K\u00fc\u00e7\u00fckler S, Sa\u011f S. Contribution of oxidative stress, apoptosis, endoplasmic reticulum stress and autophagy pathways to the Ameliorative Effects of Hesperidin in NaF-Induced Testicular toxicity. Chem Biodivers. 2023;20:e202200982.","journal-title":"Chem Biodivers"},{"key":"2107_CR39","doi-asserted-by":"publisher","first-page":"205","DOI":"10.15171\/apb.2019.024","volume":"9","author":"R Jan","year":"2019","unstructured":"Jan R, Chaudhry GE. Understanding apoptosis and apoptotic pathways targeted Cancer therapeutics. Adv Pharm Bull. 2019;9:205\u201318.","journal-title":"Adv Pharm Bull"},{"key":"2107_CR40","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1080\/01926230701320337","volume":"35","author":"S Elmore","year":"2007","unstructured":"Elmore S. Apoptosis: a review of programmed cell death. Toxicol Pathol. 2007;35:495\u2013516.","journal-title":"Toxicol Pathol"},{"key":"2107_CR41","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cbin.11137","volume":"43","author":"MS D\u2019Arcy","year":"2019","unstructured":"D\u2019Arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43:582\u201392.","journal-title":"Cell Biol Int"},{"key":"2107_CR42","doi-asserted-by":"publisher","first-page":"BSR20180992","DOI":"10.1042\/BSR20180992","volume":"39","author":"X Xu","year":"2019","unstructured":"Xu X, Lai Y, Hua ZC. Apoptosis and apoptotic body: disease message and therapeutic target potentials. Biosci Rep. 2019;39:BSR20180992.","journal-title":"Biosci Rep"},{"key":"2107_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.3892\/ijo.2014.2727","volume":"46","author":"M Mori","year":"2015","unstructured":"Mori M, Hitora T, Nakamura O, Yamagami Y, Horie R, Nishimura H, Yamamoto T. Hsp90 inhibitor induces autophagy and apoptosis in osteosarcoma cells. Int J Oncol. 2015;46:47\u201354.","journal-title":"Int J Oncol"},{"key":"2107_CR44","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1007\/s11033-021-06392-z","volume":"48","author":"A \u00d6zg\u00fcr","year":"2021","unstructured":"\u00d6zg\u00fcr A, Kara A, G\u00f6k\u015fen Tosun N, Tekin \u015e, G\u00f6k\u00e7e \u0130. Debio-0932, a second generation oral Hsp90 inhibitor, induces apoptosis in MCF-7 and MDA-MB-231 cell lines. Mol Biol Rep. 2021;48:3439\u201349.","journal-title":"Mol Biol Rep"},{"key":"2107_CR45","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3892\/ijo.2014.2399","volume":"45","author":"X Wang","year":"2014","unstructured":"Wang X, Chen M, Zhou J, Zhang X. HSP27, 70 and 90, anti-apoptotic proteins, in clinical cancer therapy (review). Int J Oncol. 2014;45:18\u201330.","journal-title":"Int J Oncol"},{"key":"2107_CR46","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3892\/or.2022.8443","volume":"49","author":"ZN Li","year":"2023","unstructured":"Li ZN, Luo Y. HSP90 inhibitors and cancer: prospects for use in targeted therapies (review). Oncol Rep. 2023;49:6.","journal-title":"Oncol Rep"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02107-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-02107-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-02107-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T04:31:20Z","timestamp":1690345880000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-02107-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,11]]},"references-count":46,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["2107"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-02107-5","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,11]]},"assertion":[{"value":"15 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have influenced the work reported in this paper.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All authors agree with the publication of this manuscript in this journal.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"234"}}